On Nov 06, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $5 to $13.
Barclays analyst Gena Wang maintains with a hold rating, and maintains the target price at $5.
Oppenheimer analyst Jay Olson maintains with a hold rating.
Stifel analyst Dae Gon Ha maintains with a buy rating, and adjusts the target price from $17 to $11.
Chardan Capital analyst Geulah Livshits maintains with a buy rating, and maintains the target price at $12.
JonesTrading analyst Soumit Roy maintains with a buy rating, and maintains the target price at $13.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The company's third quarter presented incremental progress following its strategic update.
The primary discussion among investors regarding Editas Medicine is centered on the debate if the company's new strategy marks progress or regression. The view is that reni-cel for sickle cell disease and transfusion-dependent thalassemia represents an asset with reduced risk that has potential for monetization. This asset also provides essential insights that could be advantageous as the company evaluates future strategies for their in vivo candidate.
The focus of Editas Medicine on in vivo HSPC editing is still viewed as a more efficient allocation of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update in Q1 2025, along with forthcoming updates on reni-cel BD activity.
The recent quarter is viewed as a supplementary period following a strategic change announced earlier. Editas Medicine has shifted focus towards partnering or out-licensing its leading asset for SCD/BT while concentrating on the development of its in vivo pipeline. The decision to partner SCD/BT is considered strategically appropriate given the class's gradual adoption rate. However, a cautious stance is being maintained until more advancement is seen in the in vivo pipeline.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$Editas Medicine (EDIT.US)$的評級，目標價介於5美元至13美元。
巴克萊銀行分析師Gena Wang維持持有評級，維持目標價5美元。
奧本海默控股分析師Jay Olson維持持有評級。
斯迪富分析師Dae Gon Ha維持買入評級，並將目標價從17美元下調至11美元。
Chardan Capital分析師Geulah Livshits維持買入評級，維持目標價12美元。
JonesTrading分析師Soumit Roy維持買入評級，維持目標價13美元。
此外，綜合報道，$Editas Medicine (EDIT.US)$近期主要分析師觀點如下：
該公司的第三季度在戰略更新後呈現出遞增的進展。
投資者之間關於editas medicine公司的主要討論集中在辯論公司的新策略是否標誌着進步還是退步。觀點是肆細胞貧血和依賴輸血型地中海貧血的reni-電芯代表了一項風險降低的資產，具有潛力進行貨幣化。這一資產還提供了重要見解，有助於公司評估其體內候選藥物的未來策略。
editas medicine公司專注於體內HSPC編輯仍被視爲更有效地配置其專業知識和資源以創造價值。人們正在期待2025年第一季度即將發佈的體內流水線更新，以及reni-電芯BD活動的即將更新。
最近的一個季度被看作是早前宣佈的戰略變更後的一個補充時期。editas medicine公司已將重點轉向合作或外部許可其領先的SCD/Bt資產，同時專注於開發其體內流水線。決定合作SCD/Bt被認爲在戰略上是適當的，考慮到該類別的逐漸採用率。然而，在體內流水線方面仍持謹慎態度，直到看到更多進展爲止。
以下爲今日5位分析師對$Editas Medicine (EDIT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
